Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.

Oliver FitzGeraldDafna D Gladman Phillip J Mease Christopher T Ritchlin Josef S SmolenLu GaoYanhua HuMiroslawa NowakSubhashis BanerjeeIan Catlett

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2024)

Deucravacitinib significantly impacted biomarkers associated with TYK2 signaling pathways of key inflammatory cytokines, including IL-23 and Type I IFN, and those related to collagen matrix turnover. These biomarkers may predict treatment responses to deucravacitinib.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
ankylosing spondylitis
signaling pathway
juvenile idiopathic arthritis
dendritic cells
epithelial mesenchymal transition
combination therapy
body composition
replacement therapy
tissue engineering